Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Health concerns and treatment perspectives among US adults with current versus previous high-frequency headache/migraine and acute medication overuse: The Harris Poll Migraine Report Card Survey
Headache
P14 - Poster Session 14 (11:45 AM-12:45 PM)
2-007

Migraine is a disabling neurological disease that can negatively impact all aspects of life.

To report survey results comparing the experiences of individuals with current versus previous high-frequency headache/migraine (HFM) with acute medication overuse (AMO) and to characterize self-reported experience with care in these groups. 
Respondents to this US, cross-sectional online survey qualified as living with migraine based on the validated “ID Migraine” screener. One group, labeled “current HFM+AMO,” were having ≥8 headache/migraine days/month and using ≥10 days/month of acute headache medication, while the second group (“previous HFM+AMO”) were now having ≤7 headache days/month with ≤9 days/month of acute headache medication use. Survey questions pertained to diagnosis, living with migraine, healthcare provider (HCP) communication, and treatment. Raw data were weighted to the US adult population.

US adults (N=550) were categorized as having current (n=440; mean age, 41.1yr; mean headache days/month, 15.2; mean acute headache medication days/month, 17.4 or previous (n=110; 47.2yr; 4.2days; 4.1days) HFM+AMO. Racial demographics (White [current, 57%; previous, 75%], Hispanic [24%; 13%], Black [11%; 4%]) are similar to the US population. Despite most respondents with HFM+AMO describing their overall health as “good” or “excellent” (current, 64%; previous, 72%; P=ns), 80% of current HFM+AMO) vs 66% of previous HFM+AMO expressed concern with their health (P<0.05). Of the current and previous HFM+AMO groups, 37% and 35%, respectively, wish their HCP better understood their mental/emotional health. Respondents wish HCPs discussed headache management goals with them (current, 66%; previous, 43%; P<0.05) and roughly half of both groups worry about asking too many questions (current, 47%; previous, 54%; P=ns). Current preventive treatment use was low (15-16%; P=ns), while acute medication (28-37%) and over-the-counter medication (57-59%) use was higher.

This survey revealed several areas in which HCPs can improve care, including addressing mental health concerns and optimizing acute treatment.


Authors/Disclosures
Amaal J. Starling, MD, FAAN (Mayo Clinic)
PRESENTER
Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome Therapeutics. Dr. Starling has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Starling has received personal compensation in the range of $0-$499 for serving as a Consultant for Med-IQ. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Everyday Health. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Starling has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Miller Medical. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eNeura.
Roger Cady, MD (RK Consulting, LLC) Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Meghan R. Buzby (CHAMP - Coalition for Headache and Migraine Patients) Mrs. Buzby has received personal compensation for serving as an employee of Coalition for Headache and Migraine Patients. Mrs. Buzby has a non-compensated relationship as a Advisor with Lundbeck that is relevant to AAN interests or activities.
Charles Spinale, Other (The Harris Poll) Mr. Spinale has received personal compensation for serving as an employee of The Harris Poll.
Kathy Steinberg (The Harris Poll) Ms. Steinberg has received personal compensation for serving as an employee of The Harris Poll.
Steven Kymes Steven Kymes has received personal compensation for serving as an employee of Lundbeck. Steven Kymes has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Ophthalmology. Steven Kymes has received research support from Emmes Corporation.